PBMs limiting Part D coverage of generics

A new study has cast light on the extent to which pharmacy benefit managers are favoring more expensive medications over cheaper generics and biosimilars, slowing the adoption of new, lower-cost therapies. The data could be used to propel measures in Congress to reform PBM business practices.

The study, by Avalere Health LLC, found it takes three times longer — three years versus one year — for at least half of Medicare Part D plans to cover new generics and biosimilars compared with commercial plans...